easerioushealthcareproblem,-,ESBL-producingEnterobacteriaceaeandcarbapenem-obacterbaumanniirepresentmorethan50%-orbidwithbacteremiahospital-munity-ycinATS/;171:388-(2005)guidelinesforthemanagementofadultswithHAP/VAP/HCAP血小板减少症 -来自临床的声音上市前临床试验——说明书腹泻/头痛/恶心/呕吐/%(%-%)/白细胞减少/贫血/全血细胞减少乳酸酸中毒视神经病变周围神经病变安全性&耐受性上市后监测——文献主要的SAE是血小板减少其他国家高发生率(-%)中国个案报道没有大样本人群的发生率资料&方法数据来源解放军总医院(4,000beds)使用利奈唑胺/口服/静注/序贯电子医疗记录512Patientswerescreened7Patientswereexcludedduetoyoungerthan18yearsold血小板减少症评价50585wereexcludedduetodiagnosisanddrugsHematologicaldisordersChemotherapyontumorSeverepancreatitisHepatoblastomaSystemicLupusErythmatosusantiplateletagent425wereeligibleandconsented171wereexcludedduetoplateletcountbaselineplateletanomalies(lessthan100×109/Lormorethan400×109/L)initialplateletswerenotrecordedorlessthanthreeplateletobservationpoints254wereincludedintheanalysis回顾性研究资料&方法Thrombocytopeniainthisstudy-riteriaVariablesGenderAgeBodyweightDailydose(mg/kg)durationoflinezolidadministrationlaboratorydata(5factors)AlanineaminotransferaseTotalbilirubinCreatinineAlbuminBaselineplatelet标准1——严重标准2——轻中度plateletcountlessthan100×109/L25%reductionfrombaselineplateletcountorlessthan100×109/L结果标准1 69/254 %标准2 131/254 %Ⅲ&IV度血小板下降 27/254 %输血或输注血小板 17/254 %WHOassessmentofacuteandsubacuteadverseperformanceandindexingstandardsgradeⅢ,26-49×109/LgradeⅣ,≤25×109/L研究对象概况血小板减少发生率169男性/±(range18-95)±(range2-)天CountryNumberIncidenceCriterionAutherUSA1932%plateletcountlessthan100×109/LAttassietalUSA4848%30%reductionOrricketal19%plateletcountlessthan100×109/%definedasa100×109/Ldecreasefromthebaselineora25%%definedasa100×109/Ldecreasefromthebaselineora30%%plateletcountlessthan100×109/%definedasa100×
利奈唑胺相关血小板减少知识分享 来自淘豆网m.daumloan.com转载请标明出处.
